A Life Science & Healthcare Venture Fund

Celest Therapeutics Dosed First Patient in Clinical Trial of SN301A anti-GPC3 CAR-NK in Hepatocellular Carcinoma in Collaboration with Senti Biosciences

Our Portfolio Company VFLO Medical formed Joint Venture with Inari Medical (NASDAQ: NARI) in Greater China

Merck acquired CN201, a next generation CD3XCD19 bispecific antibody from our incubated portfolio company Curon for $1.3B upfront and milestone fees

Immunitas Therapeutics to Present Preclinical Data Supporting Combination of IMT-009 with Anti-PD1 Immunotherapy at the AACR 2024 Annual Meeting

FogPharma Announces $145 Million Financing to Support Ongoing Clinical Development of FOG-001 and Accelerate Helicon Peptide Portfolio

Halda Therapeutics Named to C&E News 10 Start-Ups to Watch 2023 List

Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China

C-Ray Therapeutics Announced Approval of the First Radiation Safety License for Its Chengdu Facility in China

FogPharma Announces First Patient Dosed in Phase 1/2 Clinical Trial of First-in-class TCF-blocking β-catenin Inhibitor, FOG-001, in Advanced Solid Tumors

BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors

Dewpoint Therapeutics partners with Novo Nordisk

Halda emerges from stealth with bifunctional molecules to treat cancer

Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009

FogPharma Announces $178 Million Series D Financing to Advance Pipeline of First-in-Class Helicon Polypeptide Therapeutics Targeting Major Cancer Drivers

Soundbite Medical Enters Into A License Agreement With VFLO Medical To Bring Its Products To Greater China

Kira Pharmaceuticals Announces IND Approval from Chinese NMPA for Phase 2 Evaluation of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH)

1st Patients Dosed in Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA® in Adult Patients w/Metastatic, Hormone-Refractory Breast Cancer

Dewpoint Therapeutics Announces Completion of $150 Million Series C Financing

Ignis Therapeutics Licenses NeuroSigma eTNS Technology for ADHD in a Significant China Licensing Transaction

SK Biopharmaceuticals Enters Greater China Out-Licensing 6 Clinical Pipelines to CNS-Focused Biotech Ignis Therapeutics

Exo Therapeutics Raises $78 Million Series B Financing

Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases

OPKO Health to Develop and Commercialize RAYALDEE® in Greater China with Nicoya Therapeutics

Celest Therapeutics Dosed First Patient in Clinical Trial of SN301A anti-GPC3 CAR-NK in Hepatocellular Carcinoma in Collaboration with Senti Biosciences

Our Portfolio Company VFLO Medical formed Joint Venture with Inari Medical (NASDAQ: NARI) in Greater China

Merck acquired CN201, a next generation CD3XCD19 bispecific antibody from our incubated portfolio company Curon for $1.3B upfront and milestone fees

Immunitas Therapeutics to Present Preclinical Data Supporting Combination of IMT-009 with Anti-PD1 Immunotherapy at the AACR 2024 Annual Meeting

FogPharma Announces $145 Million Financing to Support Ongoing Clinical Development of FOG-001 and Accelerate Helicon Peptide Portfolio

Halda Therapeutics Named to C&E News 10 Start-Ups to Watch 2023 List

Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China

C-Ray Therapeutics Announced Approval of the First Radiation Safety License for Its Chengdu Facility in China

FogPharma Announces First Patient Dosed in Phase 1/2 Clinical Trial of First-in-class TCF-blocking β-catenin Inhibitor, FOG-001, in Advanced Solid Tumors

BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors

Dewpoint Therapeutics partners with Novo Nordisk

Halda emerges from stealth with bifunctional molecules to treat cancer

Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009

FogPharma Announces $178 Million Series D Financing to Advance Pipeline of First-in-Class Helicon Polypeptide Therapeutics Targeting Major Cancer Drivers

Soundbite Medical Enters Into A License Agreement With VFLO Medical To Bring Its Products To Greater China

Kira Pharmaceuticals Announces IND Approval from Chinese NMPA for Phase 2 Evaluation of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH)

1st Patients Dosed in Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA® in Adult Patients w/Metastatic, Hormone-Refractory Breast Cancer

Dewpoint Therapeutics Announces Completion of $150 Million Series C Financing

Ignis Therapeutics Licenses NeuroSigma eTNS Technology for ADHD in a Significant China Licensing Transaction

SK Biopharmaceuticals Enters Greater China Out-Licensing 6 Clinical Pipelines to CNS-Focused Biotech Ignis Therapeutics

Exo Therapeutics Raises $78 Million Series B Financing

Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases

OPKO Health to Develop and Commercialize RAYALDEE® in Greater China with Nicoya Therapeutics